Using a biologic therapy to manage rheumatoid arthritis may not significantly increase an infant’s risk for developing opportunistic infections like pneumonia, meningitis, and tuberculosis, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
The American College of Rheumatology praises Sens. Alexander and Murray for reaching a bipartisan compromise on legislation that would help stabilize the ACA insurance marketplace.
The American College of Rheumatology commends the Centers for Medicare and Medicaid Services (CMS) for finalizing its decision to withdraw the Part B Drug Payment Demonstration.
Physician and healthcare professional advocates from the American College of Rheumatology (ACR) are joined by rheumatology patients on Capitol Hill this week to urge lawmakers to address the significant drug cost and access issues affecting millions of Americans living with arthritis and other rheumatologic diseases.
“Biosimilars: To Switch or Not to Switch?” will be the focus of this year’s Great Debate at the 2017 ACR/ARHP Annual Meeting in San Diego. The debate is scheduled for 2:30 p.m. on Nov. 5 and will feature the perspectives of Dr. Jonathan Kay and Dr. Roy Fleischmann.
The American College of Rheumatology (ACR) and its public awareness campaign, Simple Tasks™, are teaming up with former NFL quarterback Terry Bradshaw to raise awareness about this growing and costly healthcare crisis during September’s Rheumatic Disease Awareness Month.
“Expanding our patients’ access to safe, effective, and affordable biologic and biosimilar therapies is a top priority of the rheumatology community. Therefore, the American College of Rheumatology applauds new legislative and regulatory developments that will expedite the approval of new therapies, increase competition, and lower the cost of these drugs.
The joint guideline between ACR and AAHKS provides eight recommendations on preoperative management of total hip and knee replacements.
Health leaders today announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
The American College of Rheumatology’s (ACR) updated clinical guideline for the prevention and treatment of Glucocorticoid-Induced Osteoporosis is now available online. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations.
The American College of Rheumatology (ACR) today expressed opposition to the Trump Administration’s proposed budget cuts to federal programs and institutions that provide critical resources in the fight against rheumatic diseases, including the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and the Children’s Health Insurance Program (CHIP). The rheumatology provider community praised budget proposals to repeal the Independent Payment Advisory Board (IPAB) and to increase funding for Graduate Medical Education (GME) programs.
Today, the American College of Rheumatology submitted comments to the U.S. Food and Drug Administration concerning the draft guidance, ‘Considerations in Demonstrating Interchangeability with a Reference Product’ (FDA 2017-01042).’
The American College of Rheumatology today praised Congressional leaders for reaching a spending deal that provides a significant boost in federal funding for medical research.
The decision by U.S. Citizenship and Immigration Services (USCIS) to suspend premium processing of H-1B visas for doctors, specialists, and other medical professionals poses an immediate and dangerous threat to chronically ill patients living in rural and underserved communities throughout the United States, warned the American College of Rheumatology (ACR) today in a letter to the Trump Administration.
The American College of Rheumatology today announced its 2017 health policy priorities, providing detailed policy recommendations to improve access to rheumatology care and address the national rheumatology workforce shortage. The policy prescriptions come in the wake of a new Centers for Disease Control and Prevention report showing arthritis prevalence is at an all-time high.
American College of Rheumatology President Sharad Lakhanpal, MBBS, MD, released a statement this morning expressing concern about the American Health Care Act's (AHCA) age-based tax credits and its failure to repeal the Independent Payment Advisory Board.
The ACR’s Simple Tasks Campaign Recognized Alongside Top National Organizations for Best PSA
The American College of Rheumatology (ACR) announced the 2016 recipients of its Master of the ACR designation, Awards of Distinction, and Distinguished Fellow Award honors during the opening lecture of the 2016 ACR/ARHP Annual Meeting in Washington D.C. These recognitions are given annually to members who exhibit outstanding contributions to the field of rheumatology.
Rheumatology practices in the United States aren’t always meeting key quality measures for patient care that may affect them as new physician reimbursement laws go into effect in the next year, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Two new studies measure the prevalence of myocardial inflammation in RA patients without known cardiovascular disease, assess how it is associated with high disease activity and show how disease-modifying therapy may decrease this type of inflammation, according to new research findings presented this week at the ACR/ARHP Annual Meeting in Washington.
Tumor necrosis factor inhibitors, a group of biologic drugs used to treat children with juvenile idiopathic arthritis, are not associated with a significantly increased risk of cancer, according to new research findings presented this week at the ACR/ARHP Annual Meeting in Washington.
The U.S. adult rheumatology workforce is in jeopardy of a serious decline, and incentives to pursue rheumatology training, including help with graduate medical education funding, could provide critical relief, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Gender and disease duration can help predict which axial spondyloarthritis patients will develop extra-articular manifestations such as uveitis, or inflammation of the eye, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Outcomes such as pain, function, range of motion, and strength after total hip arthroplasty, or joint replacement surgery, are different for men & women, which could lead to the development of sex-specific rehabilitation programs, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Lupus patients who are African-American or Asian, or those who have attained only a high school education or less, had longer delays in seeing a rheumatologist or nephrologist for a confirmed diagnosis than other groups, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
A combination of nonsteroidal anti-inflammatory drugs and TNF-inhibitors may help slow down spine damage in ankylosing spondylitis, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Patients with rheumatoid arthritis who also have lung involvement often have increased mortality, but first-line therapy with rituximab may help them live longer, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Rheumatoid arthritis patients who keep using their disease-modifying antirheumatic drugs prior to surgery do not face an increased risk of infection after their procedures, according to new research findings presented this week at the ACR/ARHP Annual Meeting in Washington.
The gut microbiomes of patients with antiphospholipid syndrome show higher levels of phospholipid-producing bacteria, and this findings point to microbes being a trigger for this life-threatening disease, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Distinct gene expression signatures in rheumatoid arthritis patients could help rheumatologists predict how these individuals will respond to tumor necrosis factor inhibitors, and may one day enable a more personalized approach to RA therapy.
Patients with RA whose rheumatologists and primary-care physicians coordinate their care have a higher likelihood of being screened for hyperlipidemia, a key risk factor for coronary heart disease, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Over a 15-year period, people with RA may have double the risk of CV events as those in the general population, rates that are similar to people with type-2 diabetes, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Patients with ankylosing spondylitis or psoriatic arthritis who take statins may have as much as a 33 percent lower mortality risk, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Three gene expression signatures can help rheumatologists predict which patients are more likely to respond to tumor necrosis factor inhibitors (TNFi) or B-cell depletion therapies in patients with moderate to severe rheumatoid arthritis.
While patients with inflammatory rheumatic diseases such as RA or spondyloarthritis are at increased risk for CVD, too few are prescribed preventive medications or meeting target goals to prevent heart-related events, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Allopurinol, a widely used treatment for lowering serum urate levels, does not appear to increase risk of kidney deterioration in gout patients with normal or near-normal kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
According to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington, most people with knee OA actually already have the physical function necessary to walk at least 6,000 steps a day, the minimum amount needed to improve their arthritis and prevent disability.
Injection of a Wnt inhibitor drug showed promise to ease pain, improve joint function, and even slow or reverse cartilage loss in patients with knee osteoarthritis, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Chronic kidney disease patients who take urate-lowering therapy and achieve target urate levels show improvement in kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
The American College of Rheumatology (ACR) praised the agency for recognizing the important role qualified clinical data registries (QCDRs) will play in the Merit-Based Incentive Payment System (MIPS) payment pathway, but expressed a number of concerns regarding the complexity and timing of requirements for small and solo practices, the absence of key cost data in the Resource Use category of MIPS, and the formidable barriers that exclude many rheumatologists from participating in the Alternative Payment Model (APM) track.
Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers and the healthcare system, during a national policy briefing held today by the nonpartisan Alliance for Health Reform.
The American College of Rheumatology has released an official statement on the MACRA proposed rule recently issued by CMS and its potential affects on the rheumatology community.
The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis.
The ACR supports the US Food and Drug Administration’s new draft guidance on biosimilars labeling and encourages additional measures that will help rheumatologists ensure the safety and efficacy of biosimilars for patients.
During a public meeting held Tuesday by the Food and Drug Administration (FDA)’s Arthritis Advisory Committee to review the license application of CT-P13, the American College of Rheumatology (ACR) provided recommendations for policy guidelines to implement as the committee decides whether to license additional biosimilars for sale in the U.S.
During a public meeting held Friday by the Food and Drug Administration (FDA), the American College of Rheumatology (ACR) expressed its support for reauthorization of the Biosimilar User Fee Act (BsUFA) and called for performance goals that encourage greater transparency in biosimilar product naming and packaging to ensure patient safety.
The American College of Rheumatology (ACR) released its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco. The guideline is designed for use by both rheumatologists and other clinicians for pharmacologic treatment decisions in commonly encountered clinical situations.
People diagnosed with rheumatoid arthritis after the year 2000 don’t have as much of an increased risk of death as people diagnosed before 2000, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco. This, suggests the researchers involved in the study, is likely due to better treatments that focus on eradicating inflammation – a major contributor to the increased risk of death in RA
Spacing exercise-based physical therapy sessions over a 12-month period while using three additional “booster” sessions periodically has been shown to be more cost effective than alternative physical therapy strategies in the treatment of knee osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
Mycophenolate mofitil is as effective as cyclophosphamide in treating interstitial lung disease in people with scleroderma, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right